Mr. Warma became interim CEO of ProMIS in Jan 2024 and has been on the Board since 2022. Prior to that he was CEO Genexine, Inc. (095700.KQ) a public, global biopharmaceutical company based in Seoul, South Korea. Previously, Mr. Warma was the US CEO/General Manager of I-Mab Biopharma U.S., (Nasdaq:IMAB) a publicly traded global biopharmaceutical company focused on oncology, where he was responsible for the expansion of global operations and a key driver in I-Mab’s U.S. IPO. Prior to that, Mr. Warma was President and CEO of Opexa Therapeutics, Inc. (Nasdaq:OPXA), a biopharmaceutical company developing novel cellular therapies. Prior to Opexa, he was CEO of Viron Therapeutics, a private biotechnology company developing novel protein-based therapeutics. Mr. Warma was in key management roles at Novartis Pharmaceuticals in Basel, Switzerland in Global Marketing and as Head of International Pharma Policy. He was also President and Co-Founder of MedExact, a health-technology company , which he later sold. Mr. Warma currently serves on the Board of Directors of the BIO. Mr. Warma obtained an honors Bachelor of Science degree specializing in neuroscience from the University of Toronto and an International MBA from the Schulich School of Business at York University in Toronto.